BA
STML

BlackRock Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

BlackRock Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$100K Buy
9,346
+346
+4% +$4.18K ﹤0.01% 3040
2016
Q3 		$97K Buy
9,000
+1,697
+23% +$13.8K ﹤0.01% 3034
2016
Q2 		$49K Hold
7,303
– – ﹤0.01% 3232
2016
Q1 		$34K Sell
7,303
-348
-5% -$1.7K ﹤0.01% 3287
2015
Q4 		$48K Sell
7,651
-3,335
-30% -$27.1K ﹤0.01% 3212
2015
Q3 		$97K Sell
10,986
-11,683
-52% -$123K ﹤0.01% 3117
2015
Q2 		$267K Buy
22,669
+14,290
+171% +$198K ﹤0.01% 2622
2015
Q1 		$121K Buy
8,379
+2,727
+48% +$41.7K ﹤0.01% 2952
2014
Q4 		$96K Sell
5,652
-14,672
-72% -$212K ﹤0.01% 3066
2014
Q3 		$253K Hold
20,324
– – ﹤0.01% 2462
2014
Q2 		$298K Buy
20,324
+572
+3% +$8.77K ﹤0.01% 2390
2014
Q1 		$402K Sell
19,752
-3,603
-15% -$87.4K ﹤0.01% 2207
2013
Q4 		$458K Buy
23,355
+7,771
+50% +$207K ﹤0.01% 2097
2013
Q3 		$706K Buy
15,584
+11,446
+277% +$373K ﹤0.01% 1660
2013
Q2 		$99K Buy
+4,138
New +$65.9K ﹤0.01% 2910

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock Advisors's STML Position: Q4 2016 in Review

BlackRock Advisors increased its Stemline Therapeutics, Inc. (STML) stake by 3.8% in Q4 2016, buying an estimated $4.18K and bringing the position to 9,346 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

BlackRock Advisors first reported a position in STML in Q2 2013 and has held it in 15 quarters since. The position peaked at $706K in Q3 2013. 74 funds tracked by Wall St. Rank hold STML as of Q4 2016.

  • BlackRock Advisors held 9,346 shares of Stemline Therapeutics, Inc. worth $100K as of Q4 2016.
  • BlackRock Advisors bought 346 Stemline Therapeutics, Inc. shares in Q4 2016, an estimated $4.18K.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3040 holding.
  • BlackRock Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Stemline Therapeutics, Inc. position peaked at $706K in Q3 2013.
  • 74 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.